首页 > 最新文献

Nephron Experimental Nephrology最新文献

英文 中文
Inhalation of Hydrogen Gas Is Beneficial for Preventing Contrast-Induced Acute Kidney Injury in Rats. 吸入氢气有利于预防大鼠因对比度引起的急性肾损伤
Pub Date : 2015-01-09 DOI: 10.1159/000369068
Koichiro Homma, Tadashi Yoshida, Maho Yamashita, Kei Hayashida, Matsuhiko Hayashi, Shingo Hori

Background: The present study aimed at investigating the effect of a novel antioxidant, hydrogen (H2) gas, on the severity of contrast-induced acute kidney injury (CIAKI) in a rat model. Methods: CIAKI was induced in rats by intravenous injection of a contrast medium, Ioversol, in addition to reagents inhibiting prostaglandin and nitric oxide synthesis. During the injection of these reagents, the rats inhaled H2 gas or control gas. Results: One day after the injection, serum levels of urea nitrogen were significantly lower in H2 gas-inhaling CIAKI rats (17.6 ± 2.3 mg/dl) than those in control gas-treated CIAKI rats (36.0 ± 7.3 mg/dl), although they both were elevated as compared to untreated rats (14.9 ± 0.9 mg/dl). Consistently, creatinine clearance in H2 gas-treated CIAKI rats was higher than that in control gas-treated counterparts. Renal histological analysis revealed that the formation of proteinaceous casts and tubular necrosis was improved by H2 gas inhalation. Mechanistic analyses showed that inhalation of H2 gas significantly reduced renal cell apoptosis, expression of cleaved caspase 3, and expression of an oxidative stress marker, 8-hydroxydeoxyguanosine, in injured kidneys. Conclusion: Results suggest that H2 gas inhalation is effective in ameliorating the severity of CIAKI in rats by reducing renal cell apoptosis and oxidative stress. © 2015 S. Karger AG, Basel.

背景:本研究旨在探讨新型抗氧化剂氢气(H2)对造影剂诱导的大鼠急性肾损伤(CIAKI)严重程度的影响。研究方法通过静脉注射造影剂 Ioversol 和抑制前列腺素和一氧化氮合成的试剂诱导大鼠急性肾损伤。在注射这些试剂期间,大鼠吸入 H2 气体或对照气体。结果显示注射一天后,吸入 H2 气体的 CIAKI 大鼠血清中的尿素氮水平(17.6 ± 2.3 mg/dl)明显低于经对照气体处理的 CIAKI 大鼠(36.0 ± 7.3 mg/dl),但与未经处理的大鼠(14.9 ± 0.9 mg/dl)相比,两者的尿素氮水平均有所升高。同样,经 H2 气体处理的 CIAKI 大鼠的肌酐清除率也高于经对照气体处理的大鼠。肾脏组织学分析表明,吸入 H2 气体可改善蛋白铸型和肾小管坏死的形成。机理分析表明,吸入 H2 气体可显著减少损伤肾脏中肾细胞的凋亡、裂解 Caspase 3 的表达以及氧化应激标志物 8-羟基脱氧鸟苷的表达。结论结果表明,吸入 H2 气体可减少肾细胞凋亡和氧化应激,从而有效改善大鼠 CIAKI 的严重程度。© 2015 S. Karger AG,巴塞尔。
{"title":"Inhalation of Hydrogen Gas Is Beneficial for Preventing Contrast-Induced Acute Kidney Injury in Rats.","authors":"Koichiro Homma, Tadashi Yoshida, Maho Yamashita, Kei Hayashida, Matsuhiko Hayashi, Shingo Hori","doi":"10.1159/000369068","DOIUrl":"10.1159/000369068","url":null,"abstract":"<p><p>Background: The present study aimed at investigating the effect of a novel antioxidant, hydrogen (H<sub>2</sub>) gas, on the severity of contrast-induced acute kidney injury (CIAKI) in a rat model. Methods: CIAKI was induced in rats by intravenous injection of a contrast medium, Ioversol, in addition to reagents inhibiting prostaglandin and nitric oxide synthesis. During the injection of these reagents, the rats inhaled H<sub>2</sub> gas or control gas. Results: One day after the injection, serum levels of urea nitrogen were significantly lower in H<sub>2</sub> gas-inhaling CIAKI rats (17.6 ± 2.3 mg/dl) than those in control gas-treated CIAKI rats (36.0 ± 7.3 mg/dl), although they both were elevated as compared to untreated rats (14.9 ± 0.9 mg/dl). Consistently, creatinine clearance in H<sub>2</sub> gas-treated CIAKI rats was higher than that in control gas-treated counterparts. Renal histological analysis revealed that the formation of proteinaceous casts and tubular necrosis was improved by H<sub>2</sub> gas inhalation. Mechanistic analyses showed that inhalation of H<sub>2</sub> gas significantly reduced renal cell apoptosis, expression of cleaved caspase 3, and expression of an oxidative stress marker, 8-hydroxydeoxyguanosine, in injured kidneys. Conclusion: Results suggest that H<sub>2</sub> gas inhalation is effective in ameliorating the severity of CIAKI in rats by reducing renal cell apoptosis and oxidative stress. © 2015 S. Karger AG, Basel.</p>","PeriodicalId":18993,"journal":{"name":"Nephron Experimental Nephrology","volume":" ","pages":"None"},"PeriodicalIF":0.0,"publicationDate":"2015-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32978007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contents Vol. 128, 2014 目录2014年第128卷
Pub Date : 2015-01-01 DOI: 10.1159/000375518
J. Latus, S. Segerer, N. Braun, D. Kitterer, J. Dippon, Simon Müller, F. Artunc, M. Alscher, Anne-Émilie Declèves, K. Sharma, J. Satriano, M. Ullian, L. Luttrell, Mi‐Hye Lee, T. Morinelli, K. Homma, Tadashi Yoshida, Maho Yamashita, K. Hayashida, M. Hayashi, S. Hori, Satz Mengensatzproduktion, Druckerei Stückle
 Chronic Kidney Disease and Hypertension A. Levin, Vancouver, B.C. R. Gansevoort, Groningen  Acute Kidney Injury R. Mehta, San Diego, Calif. N. Kolhe, Derby  Dialysis J. Daugirdas, Chicago, Ill. C. Hutchison, Hawkes Bay C. Fraansen, Groningen  Patient Subjective Experience, Healthcare Delivery and Innovation in Practice R. Fluck, Derby E. Brown, London  Crossover States with Non-Renal Organ Systems C. Chan, Toronto, Ont. T. Breidthardt, Basel N. Selby, Derby  Transplantation A. Chandraker, Boston, Mass. A. Salama, London Editor-in-Chief
慢性肾脏疾病和高血压A. Levin,温哥华,bc . R. Gansevoort,格罗宁根急性肾损伤R. Mehta,圣地亚哥,加州N. Kolhe,德比透析J. Daugirdas,芝加哥,伊利诺伊州C. Hutchison, Hawkes Bay C. Fraansen, Groningen患者主观体验,医疗保健服务和创新实践R. Fluck, Derby E. Brown, London非肾器官系统的跨界状态C. Chan,多伦多,安大略省T. Breidthardt,巴塞尔N.塞尔比,德比移植A.钱德拉克,波士顿,马萨诸塞州A.萨拉马,伦敦总编
{"title":"Contents Vol. 128, 2014","authors":"J. Latus, S. Segerer, N. Braun, D. Kitterer, J. Dippon, Simon Müller, F. Artunc, M. Alscher, Anne-Émilie Declèves, K. Sharma, J. Satriano, M. Ullian, L. Luttrell, Mi‐Hye Lee, T. Morinelli, K. Homma, Tadashi Yoshida, Maho Yamashita, K. Hayashida, M. Hayashi, S. Hori, Satz Mengensatzproduktion, Druckerei Stückle","doi":"10.1159/000375518","DOIUrl":"https://doi.org/10.1159/000375518","url":null,"abstract":" Chronic Kidney Disease and Hypertension A. Levin, Vancouver, B.C. R. Gansevoort, Groningen  Acute Kidney Injury R. Mehta, San Diego, Calif. N. Kolhe, Derby  Dialysis J. Daugirdas, Chicago, Ill. C. Hutchison, Hawkes Bay C. Fraansen, Groningen  Patient Subjective Experience, Healthcare Delivery and Innovation in Practice R. Fluck, Derby E. Brown, London  Crossover States with Non-Renal Organ Systems C. Chan, Toronto, Ont. T. Breidthardt, Basel N. Selby, Derby  Transplantation A. Chandraker, Boston, Mass. A. Salama, London Editor-in-Chief","PeriodicalId":18993,"journal":{"name":"Nephron Experimental Nephrology","volume":"128 1","pages":"I - VI"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000375518","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64772455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stimulation of Cyclooxygenase 2 Expression in Rat Peritoneal Mesothelial Cells. 刺激大鼠腹膜间皮细胞中环氧化酶 2 的表达
Pub Date : 2014-12-17 DOI: 10.1159/000368673
Michael E Ullian, Louis M Luttrell, Mi-Hye Lee, Thomas A Morinelli

Objective: Since peritoneal dialysis causes peritoneal fibrosis, we examined how glucose (osmotic factor), mannitol (osmotic control), and angiotensin II (AngII) regulate proinflammatory cyclooxygenase 2 (COX-2) in primary rat peritoneal mesothelial cells. Materials and Methods: For this study, we used the following material (n = 4-8 cell lines): cells, passages 1-2; 125I-AngII receptor surface binding (AT1R antagonist losartan, AT2R antagonist PD123319; both 10 µM); intracellular calcium probe calcium-5; COX-2 immunoblotting (β-actin normalized); real-time PCR of COX-2 gene PTGS2, and NF-κB inhibitor Ro-1069920 (5 µM). Results: AngII surface receptors were predominantly AT1R (minimally AT2R). AngII and glucose increased COX-2 protein expression concentration dependently; mannitol also increased COX-2 expression. Maximal COX-2 protein expression was observed after 6 h (AngII) and 24 h (glucose, mannitol). The time course of increases in PTGS2 mRNA levels reflected that of COX-2 protein expression. At optimal exposure conditions (time/concentration), glucose was 5-fold more efficacious in stimulating COX-2 protein expression than AngII or mannitol. Losartan fully inhibited COX-2 protein responses to AngII and mannitol, but minimally inhibited responses to glucose. Ro-1069920 fully inhibited COX-2 protein responses to each effector. Conclusion: AngII, glucose, and osmotic stress (mannitol) activate COX-2; NF-κB may be an ideal site for COX-2 blockade, and COX-2 activation by osmotic stress requires AT1R, but activation by glucose is more robust and mechanistically complex. © 2014 S. Karger AG, Basel.

目的:由于腹膜透析会导致腹膜纤维化,我们研究了葡萄糖(渗透因子)、甘露醇(渗透调节因子)和血管紧张素 II (AngII) 如何调节原代大鼠腹膜间皮细胞中的促炎性环氧化酶 2 (COX-2)。材料与方法:本研究使用了以下材料(n = 4-8 个细胞系):1-2 期细胞;125I-AngII 受体表面结合(AT1R 拮抗剂洛沙坦、AT2R 拮抗剂 PD123319;均为 10 µM);细胞内钙探针钙-5;COX-2 免疫印迹(β-肌动蛋白归一化);COX-2 基因 PTGS2 实时 PCR 和 NF-κB 抑制剂 Ro-1069920 (5 µM)。结果AngII 表面受体主要是 AT1R(极少为 AT2R)。AngII 和葡萄糖增加 COX-2 蛋白的表达与浓度有关;甘露醇也增加 COX-2 的表达。在 6 小时(AngII)和 24 小时(葡萄糖、甘露醇)后观察到 COX-2 蛋白表达的最大值。PTGS2 mRNA 水平增加的时间过程反映了 COX-2 蛋白表达的时间过程。在最佳暴露条件下(时间/浓度),葡萄糖刺激 COX-2 蛋白表达的效果是 AngII 或甘露醇的 5 倍。洛沙坦能完全抑制 COX-2 蛋白对 AngII 和甘露醇的反应,但对葡萄糖的抑制作用很小。Ro-1069920 可完全抑制 COX-2 蛋白对每种效应物的反应。结论AngII、葡萄糖和渗透压(甘露醇)可激活 COX-2;NF-κB 可能是阻断 COX-2 的理想部位,渗透压激活 COX-2 需要 AT1R,但葡萄糖激活 COX-2 的作用更强,机理更复杂。© 2014 S. Karger AG, Basel.
{"title":"Stimulation of Cyclooxygenase 2 Expression in Rat Peritoneal Mesothelial Cells.","authors":"Michael E Ullian, Louis M Luttrell, Mi-Hye Lee, Thomas A Morinelli","doi":"10.1159/000368673","DOIUrl":"10.1159/000368673","url":null,"abstract":"<p><p>Objective: Since peritoneal dialysis causes peritoneal fibrosis, we examined how glucose (osmotic factor), mannitol (osmotic control), and angiotensin II (AngII) regulate proinflammatory cyclooxygenase 2 (COX-2) in primary rat peritoneal mesothelial cells. Materials and Methods: For this study, we used the following material (n = 4-8 cell lines): cells, passages 1-2; <sup>125</sup>I-AngII receptor surface binding (AT1R antagonist losartan, AT2R antagonist PD123319; both 10 µM); intracellular calcium probe calcium-5; COX-2 immunoblotting (β-actin normalized); real-time PCR of COX-2 gene PTGS2, and NF-κB inhibitor Ro-1069920 (5 µM). Results: AngII surface receptors were predominantly AT1R (minimally AT2R). AngII and glucose increased COX-2 protein expression concentration dependently; mannitol also increased COX-2 expression. Maximal COX-2 protein expression was observed after 6 h (AngII) and 24 h (glucose, mannitol). The time course of increases in PTGS2 mRNA levels reflected that of COX-2 protein expression. At optimal exposure conditions (time/concentration), glucose was 5-fold more efficacious in stimulating COX-2 protein expression than AngII or mannitol. Losartan fully inhibited COX-2 protein responses to AngII and mannitol, but minimally inhibited responses to glucose. Ro-1069920 fully inhibited COX-2 protein responses to each effector. Conclusion: AngII, glucose, and osmotic stress (mannitol) activate COX-2; NF-κB may be an ideal site for COX-2 blockade, and COX-2 activation by osmotic stress requires AT1R, but activation by glucose is more robust and mechanistically complex. © 2014 S. Karger AG, Basel.</p>","PeriodicalId":18993,"journal":{"name":"Nephron Experimental Nephrology","volume":" ","pages":"None"},"PeriodicalIF":0.0,"publicationDate":"2014-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32928022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polyuria in Hantavirus Infection Reflects Disease Severity and Is Associated with Prolonged Hospital Stay: A Systematic Analysis of 335 Patients from Southern Germany. 汉坦病毒感染时的多尿反映了疾病的严重程度并与住院时间延长有关:对德国南部 335 名患者的系统分析。
Pub Date : 2014-12-13 DOI: 10.1159/000368934
Joerg Latus, Daniel Kitterer, Juergen Dippon, Simon Müller, Ferruh Artunc, Stephan Segerer, M Dominik Alscher, Niko Braun

Background/Aims: Puumala virus (PUUV) infection leads to nephropathia epidemica (NE), especially in endemic areas in Central Europe. The clinical course of NE is characterized by acute kidney injury (AKI) with thrombocytopenia followed by polyuria to a different degree. The prevalence of polyuria and its associated risk factors have not been reported in a large cohort of NE patients. Methods: Clinical and laboratory data during the acute phase of the disease were obtained from the medical reports and files of 335 patients who received in-hospital treatment during acute hantavirus infection. Comprehensive statistical models were developed to estimate the probability of polyuria. Results: The median age at diagnosis was 47 years (interquartile range, IQR 40-59) and 48% of the patients developed polyuria with a urinary output of 5,100 ml/day (IQR 4,200-7,300). The hospital stay was significantly longer in the polyuric group compared to the nonpolyuric group [8 days (IQR 6-10) vs. 6 days (IQR 5-8); p = 0.04]. Using logistic regression analysis, male gender (odds ratio, OR = 1.6; 95% confidence interval, CI 1.05-2.58; p = 0.03), oliguria/anuria during NE (OR = 2.56; 95% CI 1.65-4.01; p < 0.001), severe AKI (OR = 1.87; 95% CI 1.22-2.9; p < 0.001), and hematuria (OR = 1.78; 95% CI 1.02-3.15; p = 0.04) were significantly associated with the development of polyuria. In a multivariate model, the probability of polyuria was 0.19 (SEM ± 0.05) in female patients presenting with mild/moderate AKI without anuria/oliguria. Conclusions: Almost 50% of hospitalized NE patients developed polyuria, which was associated with a prolonged hospital stay. The probability of the development of polyuria was lowest in female patients with mild/moderate, non-oliguric/anuric AKI. © 2014 S. Karger AG, Basel.

背景/目的:普乌马拉病毒(PUUV)感染会导致流行性肾病(NE),尤其是在中欧的流行区。NE的临床病程特点是急性肾损伤(AKI)伴血小板减少,随后出现不同程度的多尿。关于多尿症的发病率及其相关风险因素,目前尚未在大样本 NE 患者中发现。研究方法从急性汉坦病毒感染期间接受院内治疗的 335 名患者的医疗报告和档案中获取了疾病急性期的临床和实验室数据。建立了综合统计模型来估算多尿症的概率。研究结果确诊时的中位年龄为 47 岁(四分位数间距,IQR 40-59),48% 的患者出现多尿,尿量为 5100 毫升/天(IQR 4200-7300)。多尿组的住院时间明显长于非多尿组[8 天(IQR 6-10) vs. 6 天(IQR 5-8); p = 0.04]。通过逻辑回归分析,男性(几率比,OR = 1.6;95% 置信区间,CI 1.05-2.58;P = 0.03)、NE 期间少尿/无尿(OR = 2.56;95% CI 1.65-4.01;P < 0.001)、严重 AKI(OR = 1.87;95% CI 1.22-2.9;p < 0.001)和血尿(OR = 1.78;95% CI 1.02-3.15;p = 0.04)与多尿的发生显著相关。在多变量模型中,轻度/中度 AKI 女性患者出现多尿的概率为 0.19(SEM ± 0.05),无无尿症/遗尿症。结论近 50%的住院东北大学患者出现多尿,这与住院时间延长有关。在患有轻度/中度、非胆红素尿/无尿性 AKI 的女性患者中,出现多尿的概率最低。© 2014 S. Karger AG,巴塞尔。
{"title":"Polyuria in Hantavirus Infection Reflects Disease Severity and Is Associated with Prolonged Hospital Stay: A Systematic Analysis of 335 Patients from Southern Germany.","authors":"Joerg Latus, Daniel Kitterer, Juergen Dippon, Simon Müller, Ferruh Artunc, Stephan Segerer, M Dominik Alscher, Niko Braun","doi":"10.1159/000368934","DOIUrl":"10.1159/000368934","url":null,"abstract":"<p><p>Background/Aims: Puumala virus (PUUV) infection leads to nephropathia epidemica (NE), especially in endemic areas in Central Europe. The clinical course of NE is characterized by acute kidney injury (AKI) with thrombocytopenia followed by polyuria to a different degree. The prevalence of polyuria and its associated risk factors have not been reported in a large cohort of NE patients. Methods: Clinical and laboratory data during the acute phase of the disease were obtained from the medical reports and files of 335 patients who received in-hospital treatment during acute hantavirus infection. Comprehensive statistical models were developed to estimate the probability of polyuria. Results: The median age at diagnosis was 47 years (interquartile range, IQR 40-59) and 48% of the patients developed polyuria with a urinary output of 5,100 ml/day (IQR 4,200-7,300). The hospital stay was significantly longer in the polyuric group compared to the nonpolyuric group [8 days (IQR 6-10) vs. 6 days (IQR 5-8); p = 0.04]. Using logistic regression analysis, male gender (odds ratio, OR = 1.6; 95% confidence interval, CI 1.05-2.58; p = 0.03), oliguria/anuria during NE (OR = 2.56; 95% CI 1.65-4.01; p < 0.001), severe AKI (OR = 1.87; 95% CI 1.22-2.9; p < 0.001), and hematuria (OR = 1.78; 95% CI 1.02-3.15; p = 0.04) were significantly associated with the development of polyuria. In a multivariate model, the probability of polyuria was 0.19 (SEM ± 0.05) in female patients presenting with mild/moderate AKI without anuria/oliguria. Conclusions: Almost 50% of hospitalized NE patients developed polyuria, which was associated with a prolonged hospital stay. The probability of the development of polyuria was lowest in female patients with mild/moderate, non-oliguric/anuric AKI. © 2014 S. Karger AG, Basel.</p>","PeriodicalId":18993,"journal":{"name":"Nephron Experimental Nephrology","volume":" ","pages":"None"},"PeriodicalIF":0.0,"publicationDate":"2014-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32926883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beneficial Effects of AMP-Activated Protein Kinase Agonists in Kidney Ischemia-Reperfusion: Autophagy and Cellular Stress Markers. AMP-活化蛋白激酶激动剂在肾缺血再灌注中的益处:自噬和细胞应激标志物。
Pub Date : 2014-12-06 DOI: 10.1159/000368932
Anne-Emilie Declèves, Kumar Sharma, Joseph Satriano

Background: Kidney ischemia-reperfusion is a form of acute kidney injury resulting in a cascade of cellular events prompting rapid cellular damage and suppression of kidney function. A cellular response to ischemic stress is the activation of AMP-activated protein kinase (AMPK), where AMPK induces a number of homeostatic and renoprotective mechanisms, including autophagy. However, whether autophagy is beneficial or detrimental in ischemia-reperfusion remains controversial. We investigated the effects of agonist induction of AMPK activity on autophagy and cell stress proteins in the model of kidney ischemia-reperfusion. Methods: AMPK agonists, AICAR (0.1 g/kg) and metformin (0.3 g/kg), were administered 24 h prior to ischemia, with kidneys harvested at 24 h of reperfusion. Results: We observed a paradoxical decrease in AMPK activity accompanied by increases in mammalian target of rapamycin (mTOR) C1 activity and p62/SQSTM1 expression. These results led us to propose that AMPK and autophagy are insufficient to properly counter the cellular insults in ischemia-reperfusion. Agonist induction of AMPK activity with AICAR or metformin increased macroautophagy protein LC3 and normalized p62/SQSTM1 expression and mTOR activity. Ischemia-reperfusion increases in Beclin-1 and PINK1 expressions, consistent with increased mitophagy, were also mitigated with AMPK agonists. Stress-responsive and apoptotic marker expressions increase in ischemia-reperfusion and are significantly attenuated with agonist administration, as are early indicators of fibrosis. Conclusions: Our data suggest that levels of renoprotective AMPK activity and canonical autophagy are insufficient to maintain cellular homeostasis, contributing to the progression of ischemia-reperfusion injury. We further demonstrate that induction of AMPK activity can provide beneficial cellular effects in containing injury in ischemia-reperfusion. © 2014 S. Karger AG, Basel.

背景:肾脏缺血再灌注是一种急性肾损伤,会导致一连串的细胞事件,促使细胞迅速受损并抑制肾功能。细胞对缺血应激的一种反应是激活 AMP 激活蛋白激酶(AMPK),AMPK 可诱导包括自噬在内的多种平衡和肾保护机制。然而,自噬在缺血再灌注中是有益还是有害仍存在争议。我们研究了肾缺血再灌注模型中激动剂诱导 AMPK 活性对自噬和细胞应激蛋白的影响。研究方法缺血前 24 小时给予 AMPK 激动剂 AICAR(0.1 克/千克)和二甲双胍(0.3 克/千克),再灌注 24 小时收获肾脏。结果我们观察到 AMPK 活性的下降与哺乳动物雷帕霉素靶标(mTOR)C1 活性和 p62/SQSTM1 表达的增加相矛盾。这些结果使我们提出,AMPK 和自噬不足以正确应对缺血再灌注对细胞造成的损伤。用 AICAR 或二甲双胍诱导 AMPK 活性可增加大自噬蛋白 LC3,并使 p62/SQSTM1 表达和 mTOR 活性正常化。缺血再灌注时 Beclin-1 和 PINK1 表达的增加与有丝分裂的增加一致,而 AMPK 激动剂也能缓解这种增加。应激反应和凋亡标志物的表达在缺血再灌注时会增加,服用激动剂后会显著减少,纤维化的早期指标也是如此。结论:我们的数据表明,肾脏保护性 AMPK 活性和典型自噬水平不足以维持细胞平衡,从而导致缺血再灌注损伤恶化。我们进一步证明,诱导 AMPK 活性可在缺血再灌注损伤中提供有益的细胞效应。© 2014 S. Karger AG, Basel.
{"title":"Beneficial Effects of AMP-Activated Protein Kinase Agonists in Kidney Ischemia-Reperfusion: Autophagy and Cellular Stress Markers.","authors":"Anne-Emilie Declèves, Kumar Sharma, Joseph Satriano","doi":"10.1159/000368932","DOIUrl":"10.1159/000368932","url":null,"abstract":"<p><p>Background: Kidney ischemia-reperfusion is a form of acute kidney injury resulting in a cascade of cellular events prompting rapid cellular damage and suppression of kidney function. A cellular response to ischemic stress is the activation of AMP-activated protein kinase (AMPK), where AMPK induces a number of homeostatic and renoprotective mechanisms, including autophagy. However, whether autophagy is beneficial or detrimental in ischemia-reperfusion remains controversial. We investigated the effects of agonist induction of AMPK activity on autophagy and cell stress proteins in the model of kidney ischemia-reperfusion. Methods: AMPK agonists, AICAR (0.1 g/kg) and metformin (0.3 g/kg), were administered 24 h prior to ischemia, with kidneys harvested at 24 h of reperfusion. Results: We observed a paradoxical decrease in AMPK activity accompanied by increases in mammalian target of rapamycin (mTOR) C1 activity and p62/SQSTM1 expression. These results led us to propose that AMPK and autophagy are insufficient to properly counter the cellular insults in ischemia-reperfusion. Agonist induction of AMPK activity with AICAR or metformin increased macroautophagy protein LC3 and normalized p62/SQSTM1 expression and mTOR activity. Ischemia-reperfusion increases in Beclin-1 and PINK1 expressions, consistent with increased mitophagy, were also mitigated with AMPK agonists. Stress-responsive and apoptotic marker expressions increase in ischemia-reperfusion and are significantly attenuated with agonist administration, as are early indicators of fibrosis. Conclusions: Our data suggest that levels of renoprotective AMPK activity and canonical autophagy are insufficient to maintain cellular homeostasis, contributing to the progression of ischemia-reperfusion injury. We further demonstrate that induction of AMPK activity can provide beneficial cellular effects in containing injury in ischemia-reperfusion. © 2014 S. Karger AG, Basel.</p>","PeriodicalId":18993,"journal":{"name":"Nephron Experimental Nephrology","volume":" ","pages":"None"},"PeriodicalIF":0.0,"publicationDate":"2014-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458239/pdf/nihms637786.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32904967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contents Vol. 126, 2014 目录2014年第126卷
Pub Date : 2014-07-01 DOI: 10.1159/000366182
S. O'Neill, E. Harrison, J. Ross, S. Wigmore, J. Hughes, Wanjun Zhu, Junichiro Kato, M. Nakayama, T. Yokoo, S. Ito, J. Kingma, Denys Simard, P. Voisine, J. Rouleau, B. Betz, B. Conway, Satz Mengensatzproduktion, Druckerei Stückle
{"title":"Contents Vol. 126, 2014","authors":"S. O'Neill, E. Harrison, J. Ross, S. Wigmore, J. Hughes, Wanjun Zhu, Junichiro Kato, M. Nakayama, T. Yokoo, S. Ito, J. Kingma, Denys Simard, P. Voisine, J. Rouleau, B. Betz, B. Conway, Satz Mengensatzproduktion, Druckerei Stückle","doi":"10.1159/000366182","DOIUrl":"https://doi.org/10.1159/000366182","url":null,"abstract":"","PeriodicalId":18993,"journal":{"name":"Nephron Experimental Nephrology","volume":"126 1","pages":"I - IV"},"PeriodicalIF":0.0,"publicationDate":"2014-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000366182","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64737675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Front & Back Matter 正面和背面
Pub Date : 2014-06-01 DOI: 10.1159/000365338
C. McIntyre, S. Beesley
Each paper needs an abstract of up to 250 words. It should be structured as follows: Background/Aims: What is the major problem that prompted the study? Methods: How was the study carried out? Results: Most important findings? Conclusion: Most important conclusion? Abstracts of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review.s of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review. Footnotes: Avoid footnotes. Tables and illustrations: Tables are part of the text. Place them at the end of the text file. Illustration data must be stored as separate files. Do not integrate figures into the text. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Color illustrations Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.00 per page. References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Number references in the order in which they are first mentioned in the text; do not list alphabetically. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www. icmje.org). Examples (a) Papers published in periodicals: Tomson C: Vascular calcification in chronic renal failure. Nephron Clin Pract 2003;93:c124–c130. (b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858. (c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996. (d) Edited b
每篇论文的摘要不超过250字。它的结构应该如下:背景/目的:促使这项研究的主要问题是什么?方法:研究是如何进行的?结果:最重要的发现?结论:最重要的结论?摘要综述应分为以下三个部分:背景、摘要和关键信息。背景应提供综述的简短临床背景,然后是摘要,其中应包括对文本中涵盖的主要主题的简明描述。关键信息概括了审查的主要结论。迷你评论:应分为以下几部分:背景、摘要和关键信息。背景应提供综述的简短临床背景,然后是摘要,其中应包括对文本中涵盖的主要主题的简明描述。关键信息概括了审查的主要结论。脚注:避免脚注。表格和插图:表格是课文的一部分。将它们放在文本文件的末尾。插图数据必须作为单独的文件存储。不要在正文中加入图表。电子提交的b/w半色调和彩色插图必须具有缩放后的最终分辨率为300 dpi,线条图为800-1,200 dpi之一。彩色插图在线版:彩色插图免费复制。在印刷版中,插图是黑白的。请避免提及文字和图例中的颜色。印刷版:每页最多6张彩色插图,每页800瑞士法郎。参考文献:在文本中用阿拉伯数字[方括号内]标识参考文献。提交出版但尚未被接受的材料应注明为[未发表数据],不包括在参考文献列表中。参考文献清单应只包括在文本中引用的出版物。按参考文献在文本中首次提及的顺序编号;不要按字母顺序排列。作者的姓氏和名字的首字母都应注明。除了逗号之外,不应该使用其他标点符号来分隔作者。最好注明所有作者。根据索引Medicus系统缩写期刊名称。另见国际医学期刊编辑委员会:对提交给生物医学期刊的稿件的统一要求。icmje.org)。(a)期刊上发表的论文:Tomson C:慢性肾衰竭的血管钙化。肾内科杂志,2003;19(3):344 - 344。(b)仅发表DOI号为:Theoharides TC, Boucher W, Spear K的论文:血清白细胞介素-6反映肥大细胞增多症患者的疾病严重程度和骨质疏松症。Int Arch Allergy immuno1 DOI: 10.1159/000063858。(c)专著:Matthews DE, Farewell VT:使用和理解医学统计,第3版,修订版。巴塞尔,格尔,1996。(d)主编:Kashihara N, Sugiyama H, Makino H:肾脏疾病进展中细胞凋亡的意义;在Razzaque MS,田口T(主编):肾纤维化。Contrib Nephrol。巴塞尔,Karger, 2003,第139卷,第156-172页。参考文献管理软件:建议使用EndNote,以便于管理和格式化引文和参考文献列表。数字对象标识符(DOI):较大的出版商支持将DOI作为文章的唯一标识符。DOI号将打印在每篇文章的标题页上。doi将来可以用于识别和引用没有数量或发行信息的在线发表的文章。更多信息请访问www.doi.org。补充材料仅限于对论文的科学完整性和结论没有必要的附加数据。请注意,所有补充文件将经过编辑审查,并应与原稿一起提交。编辑保留限制补充材料的范围和长度的权利。补充材料必须符合网络出版的生产质量标准,不需要任何修改或编辑。一般来说,补充文件的大小不应超过10mb。所有的图表和表格都应该有标题和图例,所有的文件都应该单独提供,并清楚地命名。可接受的文件和格式为:Word或PDF文件,Excel电子表格(仅当数据不能正确转换为PDF文件时)和视频文件(PDF格式)。Mov, .avi, .mpeg)。kager的“作者选择”服务拓宽了您的文章的覆盖范围,并使全球所有用户都可以在www上免费阅读、下载和打印。Karger.com。此选项的一次性费用为3,000瑞士法郎,这是在奖助金分配中允许的费用。更多信息请访问www.karger。com/authors_choice。美国国立卫生研究院资助的研究 根据美国国立卫生研究院(NIH)的公共访问政策,最终的、同行评议的手稿必须在正式出版之日起12个月内出现在其数字数据库中。作为对作者的一项服务,Karger代表您向PubMed Central提交文章的最终版本。对于那些选择我们的优质作者选择服务的人,我们将在发布后立即发送您的文章,加快您的工作的可访问性,而不会受到通常的封锁。关于NIH的公共访问政策的更多细节可在http://publicaccess.nih.gov/FAQ.htm#a1上获得自我存档大允许作者在其个人或机构的服务器上存档其预印本(即审稿前)或后印本(即审稿后的最终草案),前提是满足以下条件:文章不得用于商业目的,必须链接到出版商的版本,并且必须承认出版商的版权。然而,选择Karger 's Author 's ChoiceTM功能的作者也被允许存档他们文章的最终出版版本,其中包括编辑和设计改进以及引用链接。页数/论文长度印刷页数不超过3页的论文(包括表格、图表、参考文献和致谢)不收取页数费用。每增加一页或部分页数,作者需支付325.00瑞士法郎。
{"title":"Front & Back Matter","authors":"C. McIntyre, S. Beesley","doi":"10.1159/000365338","DOIUrl":"https://doi.org/10.1159/000365338","url":null,"abstract":"Each paper needs an abstract of up to 250 words. It should be structured as follows: Background/Aims: What is the major problem that prompted the study? Methods: How was the study carried out? Results: Most important findings? Conclusion: Most important conclusion? Abstracts of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review.s of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review. Footnotes: Avoid footnotes. Tables and illustrations: Tables are part of the text. Place them at the end of the text file. Illustration data must be stored as separate files. Do not integrate figures into the text. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Color illustrations Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.00 per page. References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Number references in the order in which they are first mentioned in the text; do not list alphabetically. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www. icmje.org). Examples (a) Papers published in periodicals: Tomson C: Vascular calcification in chronic renal failure. Nephron Clin Pract 2003;93:c124–c130. (b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858. (c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996. (d) Edited b","PeriodicalId":18993,"journal":{"name":"Nephron Experimental Nephrology","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000365338","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64728896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author and Subject Index Vol. 126, No. 2, 2014 作者与主题索引第126卷,2014年第2期
Pub Date : 2014-05-01 DOI: 10.1159/000362773
{"title":"Author and Subject Index Vol. 126, No. 2, 2014","authors":"","doi":"10.1159/000362773","DOIUrl":"https://doi.org/10.1159/000362773","url":null,"abstract":"","PeriodicalId":18993,"journal":{"name":"Nephron Experimental Nephrology","volume":"126 1","pages":"125 - 125"},"PeriodicalIF":0.0,"publicationDate":"2014-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000362773","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64719518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Title Page / Table of Contents 标题页/目录
Pub Date : 2014-05-01 DOI: 10.1159/000362772
{"title":"Title Page / Table of Contents","authors":"","doi":"10.1159/000362772","DOIUrl":"https://doi.org/10.1159/000362772","url":null,"abstract":"","PeriodicalId":18993,"journal":{"name":"Nephron Experimental Nephrology","volume":"126 1","pages":"I - IV"},"PeriodicalIF":0.0,"publicationDate":"2014-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000362772","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64719198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Front & Back Matter 正面和背面
Pub Date : 2014-03-28 DOI: 10.1159/000362512
Each paper needs an abstract of up to 250 words. It should be structured as follows: Background/Aims: What is the major problem that prompted the study? Methods: How was the study carried out? Results: Most important findings? Conclusion: Most important conclusion? Abstracts of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review.s of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review. Footnotes: Avoid footnotes. Tables and illustrations: Tables are part of the text. Place them at the end of the text file. Illustration data must be stored as separate files. Do not integrate figures into the text. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Color illustrations Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page. References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Number references in the order in which they are first mentioned in the text; do not list alphabetically. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www. icmje.org). Examples (a) Papers published in periodicals: Tomson C: Vascular calcification in chronic renal failure. Nephron Clin Pract 2003;93:c124–c130. (b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858. (c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996. (d) Edited bo
每篇论文的摘要不超过250字。它的结构应该如下:背景/目的:促使这项研究的主要问题是什么?方法:研究是如何进行的?结果:最重要的发现?结论:最重要的结论?摘要综述应分为以下三个部分:背景、摘要和关键信息。背景应提供综述的简短临床背景,然后是摘要,其中应包括对文本中涵盖的主要主题的简明描述。关键信息概括了审查的主要结论。迷你评论:应分为以下几部分:背景、摘要和关键信息。背景应提供综述的简短临床背景,然后是摘要,其中应包括对文本中涵盖的主要主题的简明描述。关键信息概括了审查的主要结论。脚注:避免脚注。表格和插图:表格是课文的一部分。将它们放在文本文件的末尾。插图数据必须作为单独的文件存储。不要在正文中加入图表。电子提交的b/w半色调和彩色插图必须具有缩放后的最终分辨率为300 dpi,线条图为800-1,200 dpi之一。彩色插图在线版:彩色插图免费复制。在印刷版中,插图是黑白的。请避免提及文字和图例中的颜色。印刷版:每页最多6个彩色插图可以在800瑞士法郎的文本中集成。-每页。参考文献:在文本中用阿拉伯数字[方括号内]标识参考文献。提交出版但尚未被接受的材料应注明为[未发表数据],不包括在参考文献列表中。参考文献清单应只包括在文本中引用的出版物。按参考文献在文本中首次提及的顺序编号;不要按字母顺序排列。作者的姓氏和名字的首字母都应注明。除了逗号之外,不应该使用其他标点符号来分隔作者。最好注明所有作者。根据索引Medicus系统缩写期刊名称。另见国际医学期刊编辑委员会:对提交给生物医学期刊的稿件的统一要求。icmje.org)。(a)期刊上发表的论文:Tomson C:慢性肾衰竭的血管钙化。肾内科杂志,2003;19(3):344 - 344。(b)仅发表DOI号为:Theoharides TC, Boucher W, Spear K的论文:血清白细胞介素-6反映肥大细胞增多症患者的疾病严重程度和骨质疏松症。Int Arch Allergy immuno1 DOI: 10.1159/000063858。(c)专著:Matthews DE, Farewell VT:使用和理解医学统计,第3版,修订版。巴塞尔,格尔,1996。(d)主编:Kashihara N, Sugiyama H, Makino H:肾脏疾病进展中细胞凋亡的意义;在Razzaque MS,田口T(主编):肾纤维化。Contrib Nephrol。巴塞尔,Karger, 2003,第139卷,第156-172页。参考文献管理软件:建议使用EndNote,以便于管理和格式化引文和参考文献列表。数字对象标识符(DOI):较大的出版商支持将DOI作为文章的唯一标识符。DOI号将打印在每篇文章的标题页上。doi将来可以用于识别和引用没有数量或发行信息的在线发表的文章。更多信息请访问www.doi.org。补充材料仅限于对论文的科学完整性和结论没有必要的附加数据。请注意,所有补充文件将经过编辑审查,并应与原稿一起提交。编辑保留限制补充材料的范围和长度的权利。补充材料必须符合网络出版的生产质量标准,不需要任何修改或编辑。一般来说,补充文件的大小不应超过10mb。所有的图表和表格都应该有标题和图例,所有的文件都应该单独提供,并清楚地命名。可接受的文件和格式为:Word或PDF文件,Excel电子表格(仅当数据不能正确转换为PDF文件时)和视频文件(PDF格式)。Mov, .avi, .mpeg)。kager的“作者选择”服务拓宽了您的文章的覆盖范围,并使全球所有用户都可以在www上免费阅读、下载和打印。Karger.com。一次性费用为3000瑞士法郎。-,这是拨款时可容许的费用。更多信息请访问www.karger。com/authors_choice。美国国立卫生研究院资助的研究 根据美国国立卫生研究院(NIH)的公共访问政策,最终的、同行评议的手稿必须在正式出版之日起12个月内出现在其数字数据库中。作为对作者的一项服务,Karger代表您向PubMed Central提交文章的最终版本。对于那些选择我们的优质作者选择服务的人,我们将在发布后立即发送您的文章,加快您的工作的可访问性,而不会受到通常的封锁。关于NIH的公共访问政策的更多细节可在http://publicaccess.nih.gov/FAQ.htm#a1上获得自我存档大允许作者在其个人或机构的服务器上存档其预印本(即审稿前)或后印本(即审稿后的最终草案),前提是满足以下条件:文章不得用于商业目的,必须链接到出版商的版本,并且必须承认出版商的版权。然而,选择Karger 's Author 's ChoiceTM功能的作者也被允许存档他们文章的最终出版版本,其中包括编辑和设计改进以及引用链接。页数/论文长度印刷页数不超过3页的论文(包括表格、图表、参考文献和致谢)不收取页数费用。每增加一页,作者需支付325瑞士法郎的费用。
{"title":"Front & Back Matter","authors":"","doi":"10.1159/000362512","DOIUrl":"https://doi.org/10.1159/000362512","url":null,"abstract":"Each paper needs an abstract of up to 250 words. It should be structured as follows: Background/Aims: What is the major problem that prompted the study? Methods: How was the study carried out? Results: Most important findings? Conclusion: Most important conclusion? Abstracts of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review.s of Minireviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review. Footnotes: Avoid footnotes. Tables and illustrations: Tables are part of the text. Place them at the end of the text file. Illustration data must be stored as separate files. Do not integrate figures into the text. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Color illustrations Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page. References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Number references in the order in which they are first mentioned in the text; do not list alphabetically. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www. icmje.org). Examples (a) Papers published in periodicals: Tomson C: Vascular calcification in chronic renal failure. Nephron Clin Pract 2003;93:c124–c130. (b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858. (c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996. (d) Edited bo","PeriodicalId":18993,"journal":{"name":"Nephron Experimental Nephrology","volume":"126 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000362512","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64716459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Nephron Experimental Nephrology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1